Ganciclovir-induced mutations are present in a diverse spectrum of post-transplant malignancies.
Hu FangHelen H N YanRebecca A BilardiChristoffer FlensburgHaocheng YangJayne A BarbourHoi Cheong SiuMichelle TurskiEdward ChewZhen XuSiu T LamRakesh SharmaMengya XuJunshi LiHo W IpCarol Y M CheungMichael S Y HuenE Alejandro Sweet-CorderoIan J MajewskiSuet Y LeungJason Wing Hon WongPublished in: Genome medicine (2022)
In summary, GCV can cause a diverse range of cancers. Its mutagenicity may be potentiated by other therapies, such as mycophenolate, commonly co-prescribed with GCV for post-transplant patients. Further investigation of the optimal use of these drugs could help reduce GCV-associated mutagenesis in post-transplant patients.